The study tests the autologous CAR T-cell therapy LEU011 in patients who express NGK2DL in at least 10 percent of tumor cells.

The firm must deprioritize a mitochondrial disease program in order to fast-track PBGENE-DMD to a Phase I study.

The firm is prioritizing development of its anti-DKK1 antibody sirexatamab following promising Phase II results in microsatellite-stable colorectal cancer.

Based on promising preclinical data, researchers hope to begin clinically testing PLK1-targeted treatments in young people with fibrolamellar carcinoma.

The funds will support multiple new and ongoing clinical trials of Tilt's oncolytic adenoviral therapy TILT-123.

Having established improved cancer detection, the interval cancer rate will reveal whether AI catches certain early cancers missed by standard screening.

NEW YORK – Erasca said on Tuesday it is prioritizing development of its recently acquired preclinical RAS programs, pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, and will be ...

The firm will test CAP-002 in a Phase I/IIa trial involving patients with syntaxin-binding protein 1 developmental and epileptic encephalopathy.

Researchers found the therapy downregulated VEGF expression and improved retinal thickness in neovascular age-related macular degeneration patients.

The firm will test the drug with immune checkpoint inhibitors in NSCLC patients with low PD-L1 expression and KEAP1 and/or STK11 mutations.

Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder ...